287 related articles for article (PubMed ID: 25166308)
21. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.
Williams WB; Zhang J; Jiang C; Nicely NI; Fera D; Luo K; Moody MA; Liao HX; Alam SM; Kepler TB; Ramesh A; Wiehe K; Holland JA; Bradley T; Vandergrift N; Saunders KO; Parks R; Foulger A; Xia SM; Bonsignori M; Montefiori DC; Louder M; Eaton A; Santra S; Scearce R; Sutherland L; Newman A; Bouton-Verville H; Bowman C; Bomze H; Gao F; Marshall DJ; Whitesides JF; Nie X; Kelsoe G; Reed SG; Fox CB; Clary K; Koutsoukos M; Franco D; Mascola JR; Harrison SC; Haynes BF; Verkoczy L
Nat Commun; 2017 Nov; 8(1):1732. PubMed ID: 29170366
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
[TBL] [Abstract][Full Text] [Related]
25. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
Hwang JK; Wang C; Du Z; Meyers RM; Kepler TB; Neuberg D; Kwong PD; Mascola JR; Joyce MG; Bonsignori M; Haynes BF; Yeap LS; Alt FW
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):8614-8619. PubMed ID: 28747530
[TBL] [Abstract][Full Text] [Related]
26. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
[TBL] [Abstract][Full Text] [Related]
27. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
Kong L; Ju B; Chen Y; He L; Ren L; Liu J; Hong K; Su B; Wang Z; Ozorowski G; Ji X; Hua Y; Chen Y; Deller MC; Hao Y; Feng Y; Garces F; Wilson R; Dai K; O'Dell S; McKee K; Mascola JR; Ward AB; Wyatt RT; Li Y; Wilson IA; Zhu J; Shao Y
Immunity; 2016 Apr; 44(4):939-50. PubMed ID: 27067056
[TBL] [Abstract][Full Text] [Related]
28. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
29. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
[TBL] [Abstract][Full Text] [Related]
30. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
Saunders KO; Verkoczy LK; Jiang C; Zhang J; Parks R; Chen H; Housman M; Bouton-Verville H; Shen X; Trama AM; Scearce R; Sutherland L; Santra S; Newman A; Eaton A; Xu K; Georgiev IS; Joyce MG; Tomaras GD; Bonsignori M; Reed SG; Salazar A; Mascola JR; Moody MA; Cain DW; Centlivre M; Zurawski S; Zurawski G; Erickson HP; Kwong PD; Alam SM; Levy Y; Montefiori DC; Haynes BF
Cell Rep; 2017 Dec; 21(13):3681-3690. PubMed ID: 29281818
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
32. Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire.
Altman PX; Ozorowski G; Stanfield RL; Haakenson J; Appel M; Parren M; Lee WH; Sang H; Woehl J; Saye-Francisco K; Joyce C; Song G; Porter K; Landais E; Andrabi R; Wilson IA; Ward AB; Mwangi W; Smider VV; Burton DR; Sok D
bioRxiv; 2024 Feb; ():. PubMed ID: 38405899
[TBL] [Abstract][Full Text] [Related]
33. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
[TBL] [Abstract][Full Text] [Related]
34. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins.
Chen F; Tzarum N; Lin X; Giang E; Velázquez-Moctezuma R; Augestad EH; Nagy K; He L; Hernandez M; Fouch ME; Grinyó A; Chavez D; Doranz BJ; Prentoe J; Stanfield RL; Lanford R; Bukh J; Wilson IA; Zhu J; Law M
Immunity; 2021 Apr; 54(4):781-796.e4. PubMed ID: 33675683
[TBL] [Abstract][Full Text] [Related]
35. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.
Strokappe N; Szynol A; Aasa-Chapman M; Gorlani A; Forsman Quigley A; Hulsik DL; Chen L; Weiss R; de Haard H; Verrips T
PLoS One; 2012; 7(3):e33298. PubMed ID: 22438910
[TBL] [Abstract][Full Text] [Related]
36. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
Li Y; O'Dell S; Walker LM; Wu X; Guenaga J; Feng Y; Schmidt SD; McKee K; Louder MK; Ledgerwood JE; Graham BS; Haynes BF; Burton DR; Wyatt RT; Mascola JR
J Virol; 2011 Sep; 85(17):8954-67. PubMed ID: 21715490
[TBL] [Abstract][Full Text] [Related]
38. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of variable heavy and light chain regions of five HIV type 1-specific human monoclonal antibodies.
van der Donk EM; Schutten M; Osterhaus AD; van der Heijden RW
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1639-49. PubMed ID: 7888223
[TBL] [Abstract][Full Text] [Related]
40. Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.
Phad GE; Vázquez Bernat N; Feng Y; Ingale J; Martinez Murillo PA; O'Dell S; Li Y; Mascola JR; Sundling C; Wyatt RT; Karlsson Hedestam GB
J Immunol; 2015 Jun; 194(12):5903-14. PubMed ID: 25964491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
